Why Cleveland Clinic’s Adoption of CT:VQ™ Could Change Lung Diagnostics Forever
4DMedical secures Cleveland Clinic as the third major US academic medical centre to adopt its CT – VQ™ respiratory imaging technology, marking rapid commercial traction post-FDA clearance.
- Cleveland Clinic begins clinical use of CT – VQ™ under commercial arrangement
- Third leading US academic medical centre to adopt CT – VQ™ within three months
- Introductory pricing period supports clinical workflow integration
- Validates 4DMedical’s commercialisation strategy and technology
- Partnerships with Philips and top AMCs aim to accelerate broader adoption
A Milestone for 4DMedical
4DMedical Limited (ASX – 4DX) has announced a significant commercial breakthrough with the Cleveland Clinic, one of the world’s most prestigious healthcare institutions, commencing clinical use of its CT – VQ™ respiratory imaging technology. This adoption follows closely on the heels of similar agreements with Stanford University and the University of Miami, positioning CT – VQ™ as a rapidly emerging standard in advanced lung diagnostics.
The Cleveland Clinic’s decision to integrate CT – VQ™ into its clinical workflow is a strong endorsement of 4DMedical’s patented XV Technology®, which transforms conventional CT scans into detailed functional images of lung ventilation and perfusion. This capability offers clinicians a more precise and earlier detection of respiratory diseases compared to traditional nuclear ventilation-perfusion imaging.
Strategic Commercialisation and Market Validation
The commercial arrangement includes a one-month introductory pricing period designed to facilitate seamless clinical integration before transitioning to full commercial terms. This approach reflects 4DMedical’s proven commercialisation model, which has already secured rapid adoption by three leading US academic medical centres within just over three months of FDA clearance.
Andreas Fouras, 4DMedical’s MD and CEO, highlighted the significance of this milestone, noting that Cleveland Clinic’s endorsement validates both the technology and the company’s strategic focus on elite academic medical centres. These institutions serve as influential reference sites, enhancing credibility and accelerating adoption across broader hospital networks, especially when combined with 4DMedical’s partnership with Philips.
Implications for Respiratory Care and Market Expansion
The adoption of CT – VQ™ by such high-profile centres signals a shift in cardiothoracic imaging standards, with potential to improve patient outcomes through more personalised and precise respiratory diagnostics. Delivered via a Software-as-a-Service model, 4DMedical’s solutions integrate smoothly into existing hospital infrastructure, enhancing physician productivity and enabling earlier intervention for lung diseases.
Looking ahead, the momentum gained from these deployments positions 4DMedical to expand its footprint beyond academic centres into national health systems and community hospitals, leveraging clinical validation and operational advantages demonstrated at these flagship sites.
Bottom Line?
With Cleveland Clinic onboard, 4DMedical’s CT – VQ™ is poised to redefine respiratory diagnostics across US healthcare.
Questions in the middle?
- How will Cleveland Clinic’s clinical outcomes influence wider US hospital adoption?
- What are the long-term commercial terms following the introductory pricing period?
- How will 4DMedical’s partnership with Philips accelerate integration into community hospitals?
